Both SOAT1 knockdown and treatment with avasimibe, a SOAT1 inhibitor, reduced the cholesterol levels in the plasma membrane, inhibited the integrin and TGFβ signaling pathways, and ultimately suppressed the proliferation and migration of HCC cells. Here, SOAT1 is linked to hepatocellular carcinoma.